Novocure Receives CE Mark for Locally Advanced Pancreatic Cancer

Key Facts

1Novocure (NASDAQ: NVCR) announced that Optune Pax has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel.

In a development that expands treatment options for a difficult-to-treat cancer, Novocure (NASDAQ: NVCR) announced that its Optune Pax device has received CE Mark for treating adults with locally advanced exocrine pancreatic cancer. The device is used concurrently with a regimen of gemcitabine and nab-paclitaxel, according to a company press release. The regulatory approval marks a significant expansion of the device's approved indications in Europe.

Locally advanced pancreatic cancer presents a major treatment challenge due to limited available options. The CE Mark enables market entry in Europe, strengthening Novocure's footprint in oncology. The decision follows clinical evidence demonstrating the device's efficacy with chemotherapy, opening a new patient segment.

NVCR shares closed at $15.48 on June 29, trading in a range between $15.14 and $15.60. The new approval may serve as a positive catalyst, particularly with potential revenue expansion in Europe. Investors will watch for updates on commercial launch plans and any regulatory developments in other regions.